Annually in the U.S., at least 3.5 million people are treated for traumatic brain injuries (TBI). A recent article published in the Journal of the American Medical Association’s neurology section reports that the development of therapies for TBI has been limited by the absence of diagnostic and prognostic biomarkers. The microtubule-associated protein Tau is an axonal phosphoprotein. Up to now, the presence of the protein in plasma from patients with acute TBI and chronic TBI has not been investigated.
Traumatic brain injury (TBI) is considered an event and/or a disease. Traumatic brain injuries may lead to chronic functional, neurocognitive and neuropsychiatric deficits. The three classifications of a TBI are measured by severity, which can be mild, moderate or severe.
There were more than 3.5 million emergency department visits for TBI and more than 280,000 patients are hospitalized annually with TBI; most of these are classified as mild TBI. It is presumed that there are many more individuals who have mild TBI, but do not seek medical attention. Between 2000 and 2014, more than 300,000 members of the military sustained TBI during combat and training. Approximately half of the patients with TBI in the U.S. have at least some short-term disability related to that injury or illness. TBI is associated with an increased risk of neurodegenerative disorder such as Alzheimer’s disease, which can occur in individuals years after the injury.